Skip to main content
Clinical Trials/ACTRN12613000419763
ACTRN12613000419763
Not yet recruiting
未知

An open-label, prospective pilot study evaluating the effect of adalimumab on endothelial function and on cardiovascular biomarkers in severe chronic plaque psoriasis patients eligible for biologic treatment in Australia

Dr Anna Braue0 sites15 target enrollmentApril 15, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
Chronic plaque psoriasis
Sponsor
Dr Anna Braue
Enrollment
15
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 15, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr Anna Braue

Eligibility Criteria

Inclusion Criteria

  • Patient who has had severe chronic plaque psoriasis for at least 6 months with no previous exposure to biologics, and is eligible for biologics as per Australian PBS requirements and has been selected to start adalimumab by a dermatologist

Exclusion Criteria

  • Patients not starting on adalimumab as their first biological agent or has had prior biologic treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials